XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) Stock Price

XTLBStock
$2.6048.20%52W
Market Cap$6.39M
P/E
PEG Ratio2.27
Div yield
Beta0.76

XTLB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-40.71%
Price vs S&P 500 (4W)-8.37%
PEG Ratio2.27
VGM Score30.81

XTLB Earnings Surprise History

Q2 15-0.02est. 0.00
Q3 15-0.02est. -0.20
Q4 15-0.06est. 0.00
Q1 16-0.04est. 0.00

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
XTLBXTL Biopharmaceuticals Ltd. American Depositary Shares
D$2.60
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About XTL Biopharmaceuticals Ltd. American Depositary Shares

XTL Biopharmaceuticals develops therapeutics for unmet medical needs in autoimmune and oncology indications. Its lead candidate, hCDR1, is a synthetic peptide in Phase II development for systemic lupus erythematosus and Sjögren's syndrome. The company is also advancing rHuEPO, a recombinant human erythropoietin, to extend survival in multiple myeloma patients.